健脾中药复方胃肠安对人胃癌裸小鼠

1,1,2,1,2,1(1.,200032;2.,200032)[]::SGC-7901,66,41,253:,5-FU0.12g/ml0.5ml,1/d;5-FU5-FU50mg/kg,1/;0.5ml/d64;41,,(pro-liferatingcellnuclearantigen,PCNA):,5-FU40.82%37.92%;48.70%60.10%,5-FU,330.77%28.57%71.43%(P0.05),5-FUPCNA,,(P0.05P0.01)5-FUPCNA,,5-FU(P0.05):,[];();;[]R286.91;R735.2[]A[]1672-1977(2005)05-0378-04Growth-inhibitingandanti-metastasiseffectsofWeichanganDecoctiononorthotopictransplantnudemousemodelofhumangastriccancerZHAOHai-Lei1,ZHAOAi-Guang1,YOUSheng-Fu2,GUYing1,TANGLai-Di2,YANGJin-Kun1(1.DepartmentofOncology,LonghuaHospital,ShanghaiUniversityofTraditionalChineseMedicine,Shanghai200032,China;2.ScienceandResearchLaboratory,LonghuaHospital,ShanghaiUniversityofTraditionalChineseMedicine,Shanghai200032,China)ABSTRACTObjective:Toevaluatethegrowth-inhibitingandanti-metastasiseffectsofWeichanganDecoc-tion(WCAD)onorthotopictransplantnudemousemodelofhumangastriccancer.Methods:Forty-onenudemicewereimplantedwithSGC-7901cellsatorthotopicsite,whereas25wereimplantedwithSGC-7901cellssubcutaneously.ThenthenudemiceineachtransplantationmodelweredividedintothesamethreegroupswhichwereWCAD-treatedgroupwithWCAD0.5ml/dtakenorally,5-FU-treatedgroupwith5-FU50mg/kgintraperitoneallyinjectedweeklyanduntreatedcontrolgroupwithphysiologicalsaline0.5ml/dtakenorally.Thegrowth-inhibitingratesoftransplanttumorsweredetectedandthemetastaticlesionswereexaminedintheorthotopictransplantmousemodelwhilePCNA-positiverateandapoptoticindex(AI)wereobservedin8732005935JChinIntegrMed,September2005,Vol.3,No.5[](No.02QB14043);(No.1C06)[](1972-),,,.Correspondenceto:ZHAOAi-Guang,MD,AssociateProfessor.E-mail:[e-mail]:Thegrowth-inhibitingratesintheWCAD-treatedand5-FU-treatedgroupsoforthotopictransplantmousemodelwere40.82%and37.92%respectivelywhereasthoseofsubcutaneoustransplantmousemodelwere48.70%and60.10%.Theincidenceratesofmetastasisinperigastriclymphnotes,lymphnodesintheportahepatis,liver,diaphragmandperitoneumintheWCAD-treatedand5-FU-treatedgroupswerelowerthanthoseintheuntreatedcontrolgroup,andthetotalmetasta-sisratesintheWCAD-treated,5-FU-treatedandtheuntreatedcontrolgroupswere30.77%,28.57%and71.43%respectivelywithsignificantdifferences(P0.05).ThetotalPCNA-positiveratesintheWCAD-treatedand5-FU-treatedgroupswereobviouslylowerthanthatintheuntreatedcontrolgroup(P0.05orP0.01)whiletheAIwashigherthanthatintheuntreatedcontrolgroup(P0.01).Thegrowth-inhibitingrate,totalPCNA-positiverateandtotalmetastasisrateintheWCAD-treatedgrouphadnosignificantdiffer-encesascomparedwiththoseinthe5-FU-treatedgroup,buttheAIintheWCAD-treatedgroupwassignifi-cantlyhigherthanthatinthe5-FU-treatedgroup(P0.05).Conclusion:WCADhastheinhibitingeffectsontumorgrowthandmetastasisofgastriccancerwhichisorthotopicimplantedontonudemice.Thiseffectmaybeobtainedbyproliferationsuppressionandapoptosisinductionincancer.KEYWORDSstomachneoplasms;compounds(TCD);neoplasmtransplantation;apoptosisJChinIntegrMed,2005,3(5):378-381[1,2](WeichanganDecoction,WCAD),,[3],,[4],,,,11.11.1.167BALB/C-nu/nu66,1822g,1.1.2SGC-7901,,31.1.3,0.12g/ml;5-FU,(:030601),2.5mg/ml5-FU1.21.2.1(1)[5]664112h,20mg/kg,,,3mm(150mg),,,,(0.5cm),,,413:13,5-FU141428,,0.5ml/d;5-FU5-FU,50mg/kg,1;,0.5ml/d6364(2)25,1.5mm3:8,5-FU98,0.5ml/d;5-FU5-FU,50mg/kg,1;,0.5ml/d40411.2.2(1)9732005935JChinIntegrMed,September2005,Vol.3,No.5(2),,=(-)/100%(3),(4)(proliferatingcellnuclearantigen,PCNA)PCNA3,3’-(3,3’-diaminobenzidine,DAB),[6]dUTP[7],,KCalbiochem1.3SPSS10.0,,22.15-FU(1.821.42)g(1.911.12)g,(3.081.68)g,(P0.05);5-FU40.82%37.92%5-FU(0.990.76)g(0.770.48)g,(1.930.58)g,(P0.05P0.01);5-FU,;5-FU48.70%60.10%2.25-FU,;5-FU,(P0.05);5-FU12.3PCNA5-FUPCNA,(P0.05P0.01);PCNA5-FU,;5-FU,(P0.01);5-FU,(P0.05)21Tab1Tumormetastasisoforthotopictransplantnudemousemodelofhumangastriccancerin3groups(%)GroupnPerigastriclymphnodesLiverLymphnodesintheportahepatisDiaphragmPeritoneumTotalmetastasisrateWCAD-treated13F0¢7C.69(1/13)0™7q.69(1/13)15.38(2/13)30†.77(4/13)*5-FU-treated14F0¢21X.43(3/14)0™0)14.29(2/14)28†.57(4/14)*Untreatedcontrol14F7ê.14(1/14)50(7/14)28è.57(4/14)28x.57(4/14)42.86(6/14)71ƒ.43(10/14)*P0.05,vsuntreatedcontrolgroup2PCNATab2ExpressionofPCNAandapoptoticindexinsubcutaneoustransplantnudemousemodelofhumangastriccancerin3groups(xs,%)GroupnTotalPCNA-positiverateApoptoticindexWCAD-treated8A39ý.037.37**9].724.51**5-FU-treated9A43ý.4819.77*5].741.75**Untreatedcontrol8A62ý.2613.802].451.37*P0.05,**P0.01,vsuntreatedcontrolgroup;P0.05,vs5-FU-treatedgroup3,:[3],,,0832005935JChinIntegrMed,September2005,Vol.3,No.5SGC-7901,5-FU,;,41100%,,,:5-FU,[4],5-FUSGC-7901,(),71.43%5-FU7.69%,5-FU21.43%,,,;5-FU5-FU5-FU:,,PCNA35000,:PCNA[8],,PCNA,5-FU,,,,,5-FU5-FU,,,,[]1.[J].,2002,24(2):203-204.2.93[J].,2004,45(6):441-442.3,,,.[J].,1992,33(8):23-25.4,,.[J].,2000,8(7):737-740.5,,,.[J].,2001,9(4):198-200.6,,,.IL-1IL-2[J].,1998,5(3):214,203.7ZhaoAG,ZhaoHL,JinXJ,etal.EffectsofChineseJianpiherbsoncellapoptosisandrelatedgeneexpressioninhumangastriccancergraftedontonudemice[J].WorldJGastroentrerol,2002,8(5):792-